Oric Pharmaceuticals Stock Performance
| ORIC Stock | USD 7.91 0.12 1.54% |
The company holds a Beta of 1.99, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oric Pharmaceuticals will likely underperform. Oric Pharmaceuticals right now holds a risk of 5.73%. Please check Oric Pharmaceuticals total risk alpha, accumulation distribution, period momentum indicator, as well as the relationship between the potential upside and day median price , to decide if Oric Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Oric Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound forward indicators, Oric Pharmaceuticals is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 1.54 | Five Day Return 2.2 | Year To Date Return (4.24) | Ten Year Return (69.31) | All Time Return (69.31) |
1 | Disposition of 24660 shares by Chacko Jacob of Oric Pharmaceuticals at 8.2812 subject to Rule 16b-3 | 12/16/2024 |
2 | Acquisition by Chacko Jacob of 300000 shares of Oric Pharmaceuticals at 4.36 subject to Rule 16b-3 | 12/27/2024 |
3 | Acquisition by Chacko Jacob of 100000 shares of Oric Pharmaceuticals subject to Rule 16b-3 | 01/02/2025 |
4 | ORIC Pharmaceuticals Sees Unusually-High Trading Volume - Whats Next - MarketBeat | 01/07/2025 |
5 | ORIC Pharmaceuticals Shares Up 5.6 percent - Should You Buy - MarketBeat | 01/24/2025 |
6 | Acquisition by Kunkel Lori Anne of 25600 shares of Oric Pharmaceuticals at 7.9 subject to Rule 16b-3 | 01/27/2025 |
7 | Citi maintains ORIC stock Buy rating, 13 target ahead of PFE data - MSN | 02/04/2025 |
8 | ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 | 02/07/2025 |
9 | JPMorgan Chase Co. Forecasts Strong Price Appreciation for ORIC Pharmaceuticals Stock - MarketBeat | 02/10/2025 |
10 | Buy Rating on Oric Pharmaceuticals Capitalizing on Prostate Cancer Treatment Advances - TipRanks | 02/14/2025 |
11 | ORICPharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates | 02/18/2025 |
12 | ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones | 02/25/2025 |
13 | Acquisition by Chacko Jacob of 600000 shares of Oric Pharmaceuticals at 8.26 subject to Rule 16b-3 | 02/28/2025 |
14 | Brokerages Set ORIC Pharmaceuticals, Inc. Target Price at 18.86 - MarketBeat | 03/05/2025 |
| Begin Period Cash Flow | 23.9 M |
Oric |
Oric Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 825.00 in Oric Pharmaceuticals on December 17, 2024 and sell it today you would lose (46.00) from holding Oric Pharmaceuticals or give up 5.58% of portfolio value over 90 days. Oric Pharmaceuticals is currently generating 0.0642% in daily expected returns and assumes 5.731% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Oric, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oric Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oric Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oric Pharmaceuticals, and traders can use it to determine the average amount a Oric Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0112
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ORIC | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.73 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Oric Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oric Pharmaceuticals by adding Oric Pharmaceuticals to a well-diversified portfolio.
Oric Pharmaceuticals Fundamentals Growth
Oric Stock prices reflect investors' perceptions of the future prospects and financial health of Oric Pharmaceuticals, and Oric Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oric Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 300.52 M | ||||
| Shares Outstanding | 71.03 M | ||||
| Price To Book | 2.28 X | ||||
| EBITDA | (142.9 M) | ||||
| Net Income | (127.85 M) | ||||
| Cash And Equivalents | 227.06 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 3.18 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 18.72 X | ||||
| Book Value Per Share | 3.42 X | ||||
| Cash Flow From Operations | (112.66 M) | ||||
| Earnings Per Share | (1.83) X | ||||
| Market Capitalization | 553.3 M | ||||
| Total Asset | 274.14 M | ||||
| Retained Earnings | (562.77 M) | ||||
| Working Capital | 237.4 M | ||||
About Oric Pharmaceuticals Performance
By analyzing Oric Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Oric Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oric Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oric Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.57) | (0.60) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.53) | (0.55) |
Things to note about Oric Pharmaceuticals performance evaluation
Checking the ongoing alerts about Oric Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oric Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oric Pharmaceuticals had very high historical volatility over the last 90 days | |
| Oric Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (127.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oric Pharmaceuticals currently holds about 227.06 M in cash with (112.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Oric Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 |
- Analyzing Oric Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oric Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Oric Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oric Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oric Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oric Pharmaceuticals' stock. These opinions can provide insight into Oric Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Oric Stock analysis
When running Oric Pharmaceuticals' price analysis, check to measure Oric Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oric Pharmaceuticals is operating at the current time. Most of Oric Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oric Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oric Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oric Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |